Management of capecitabine-induced hand-foot syndrome by local phytotherapy

被引：3

作者：

Kern E. ^{[1
,2
,4
]}

Schmidinger M. ^{[3
]}

Locker G.J. ^{[3
]}

Kopp B. ^{[2
]}

机构：

[1] Anstaltsapotheke des Krankenhauses der Barmherzigen Schwestern, Linz

[2] Department für Pharmakognosie, Universität Wien, Wien

[3] Universitätsklinik für Innere Medizin I, Medizinische Universität Wien, Wien

[4] Anstaltsapotheke des Krankenhauses der Barmherzigen Schwestern, 4010 Linz

来源：

Wiener Medizinische Wochenschrift | 2007年 / 157卷 / 13-14期

关键词：

Calendula officinalis L; Capecitabine; Hand-foot syndrome; Matricaria recutita L; Salvia officinalis L;

D O I：

10.1007/s10354-007-0435-5

中图分类号：

学科分类号：

摘要：

The so-called hand-foot syndrome (HFS) is a dose-limiting side effect with only rare therapeutic options in cancer patients treated with capecitabine (Xeloda®). Depending on the intensity of the skin reaction dose reduction, interruption or even the break-off of capecitabine therapy is necessary. We therefore try to describe a new and promising alternative treatment of the hand-foot syndrome, a local therapy with a mixture of herbal medicinal products mainly consisting of hand- and foot baths, and present the promising results of this treatment modality observed in 11 consecutive patients. © Springer-Verlag 2007.

引用

页码：337 / 342

页数：5

共 17 条

[1]

Austria-Codex, Fachinformation Band, 4, pp. 8017-8025, (2006)

[2]

Scheithauer W., Blum J., Et al., Coming to grips with hand-foot syndrome: Insights from clinical trials evaluating capecitabine, Oncology, 18, pp. 1161-1168, (2004)

[3]

Gressett S.M., Stanford B.L., Hardwicke F., Management of hand-foot syndrome induced by capecitabine, J Oncol Pharm Pract, 12, 3, pp. 131-141, (2006)

[4]

Lopez A.M., Wallace L., Dorr R.T., Koff M., Hersh E.M., Alberts D.S., Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia, Cancer Chemother Pharmacol, 44, 4, pp. 303-306, (1999)

[5]

Brown J., Burck K., Black D., Et al., Treatment of cytarabine acral erythema with corticosteroids, J Am Acad Dermatol, 24, pp. 1023-1025, (1991)

[6]

Titgan M.A., Prevention of palmar-plantar erythrodysesthesia associated with liposome-encapsulated Doxorubicin (Doxil) by oral dexamethasone, Proc Am Soc Clin Oncol, 16, (1997)

[7]

Salzberg M., Herrmann R., Das Hand-Fuss-Syndrom (palmar-plantare Erythrodysästhesie), Schweiz Med Wochenschr, 130, 40, pp. 1413-1416, (2000)

[8]

Vail D.M., Chun R., Thamm D.H., Et al., Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: A randomized, double-blind clinical trial using a canine model, Clin Cancer Res, 4, pp. 1567-1571, (1998)

[9]

Kara I.O., Sahin B., Erkisi M., Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction. Breast 15(3): 414-424, Epub, (2006)

[10]

Lin E., Morris J.S., Ayers G.D., Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity, Oncology (Huntingt), 16, pp. 31-37, (2002)

← 1 2 →